A complex probiotic for alleviating acute lung injury and application thereof

The composite probiotics of Bifidobacterium animalis YRK-12 and Lactobacillus rhamnosus LRa-Y8 work synergistically to alleviate acute lung injury, solving the problem of limited efficacy of a single probiotic and achieving safe and efficient treatment of lung injury.

CN120617325BActive Publication Date: 2025-10-21YIRUIKANG BIOTECHNOLOGY (HAINAN) CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202511128404.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-08-13
Publication Date
2025-10-21
Estimated Expiration
2045-08-13

AI Technical Summary

Technical Problem

There is a lack of efficient and safe methods for treating acute lung injury in the current technology. The efficacy of single probiotics is limited, and traditional drugs have problems with side effects and drug resistance.

Method used

A composite probiotic consisting of Bifidobacterium animalis YRK-12 and Lactobacillus rhamnosus LRa-Y8 is used in the form of an oral preparation to synergistically reduce the rate of weight loss, improve lung pathological damage, and regulate the balance of inflammatory factors.

Benefits of technology

It is significantly superior to single strains, exhibits synergistic effects, has high safety, can maintain the integrity of alveolar structure, reduce inflammatory cell infiltration and interstitial edema, downregulate pro-inflammatory factors, upregulate anti-inflammatory factors, block the inflammatory cascade amplification effect, and avoid the side effects of mechanical ventilation and traditional drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120617325B_ABST
    Figure CN120617325B_ABST
Patent Text Reader

Abstract

The application provides a kind of composite probiotic for relieving acute lung injury and application thereof, and specifically discloses a kind of composite probiotic consisting of animal bifidobacterium YRK-12 and rhamnose lactobacillus casei LRa-Y8 in the preparation of drug for relieving acute lung injury;Among them, the animal bifidobacterium YRK-12, the preservation number is CGMCC No.28597;Rhamnose lactobacillus casei LRa-Y8, the preservation number is CGMCC No.34186.Experimental verification shows that the composite probiotic can significantly relieve acute lung injury induced by lipopolysaccharide (LPS) through synergistic effect, specifically manifested as reducing the weight loss rate of mice, improving lung tissue pathological injury (maintaining alveolar structure integrity, reducing inflammatory cell infiltration), down-regulating the level of pro-inflammatory factors (IL-1β, TNF-α, IL-6) in serum and lung tissue and up-regulating the level of anti-inflammatory factors (IL-4), thereby regulating lung immune balance through "gut-lung axis", providing a safe and effective new microecological regulation strategy for prevention and treatment of acute lung injury.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Probiotic agent for improving viral pneumonia and application thereof

    CN117959343A

  • Bifidobacterium animalis and semen raphani composition capable of synergistically preventing and treating functional constipation

    CN118593558A